Victoria Zazulina

Research interests

Publications

• Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30033-x

• First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

  Journal of Thoracic Oncology · 2016 · https://doi.org/10.1016/j.jtho.2015.11.014

• Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00026-1

• Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(14)71173-8

• Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.44.2806

• Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.46.1764

Current projects

No projects listed.